Table 4 Summary of on-therapy drug-related adverse events (any grade) occurring in ≥ 20% of patients in either treatment arm (Safety population)
| Â | Asian patients, n (%) | Non-Asian patients, n (%) | ||
|---|---|---|---|---|
Preferred term | Pazopanib (n = 186) | Sunitinib (n = 177) | Pazopanib (n = 348) | Sunitinib (n = 355) |
Neutropenia | 41 (22) | 74 (42) | 15 (4) | 62 (17) |
Neutrophil count decreased | 26 (14) | 46 (26) | 1 (< 1) | 13 (4) |
Neutropenia/neutrophil count decreaseda | 67 (36) | 120 (68) | 16 (5) | 75 (21) |
Leukopenia | 37 (20) | 58 (33) | 9 (3) | 38 (11) |
WBC count decreased | 23 (12) | 51 (29) | 3 (< 1) | 16 (5) |
Leukopenia/WBC count decreaseda | 60 (32) | 109 (62) | 12 (4) | 54 (15) |
Platelet count decreased | 29 (16) | 62 (35) | 5 (1) | 30 (8) |
Thrombocytopenia | 29 (16) | 81 (46) | 23 (7) | 94 (26) |
Thrombocytopenia/platelet count decreaseda | 58 (31) | 143 (81) | 28 (8) | 124 (35) |
Hemoglobin decreased | 19 (10) | 42 (24) | 5 (1) | 13 (4) |
Anemia | 12 (6) | 46 (26) | 15 (4) | 38 (11) |
Anemia/hemoglobin decreaseda | 31 (17) | 88 (50) | 20 (6) | 51 (14) |